Wednesday, July 8, 2026

Patent intelligence · US

US 11525120

Stem cell derived islet differentiation

granted A61KA61K2035/126A61K35/39A61P
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 16
Applicant portfolio 991
Patent details — US 11525120
Jurisdiction
US
Status
granted
Grant date
Dec 13, 2022
Expiration
Dec 8, 2042
Claims
26
CPC classes
A61K, A61K2035/126, A61K35/39, A61P
View on Google Patents ↗

Quick answer

US 11525120 (Stem cell derived islet differentiation) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
26
CPC classes
A61K, A61K2035/126, A61K35/39, A61P, A61P5/50

More from Vertex Pharmaceuticals Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  2. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  3. US 12384790

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  4. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  5. US 12385013

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  6. US 12377252

    Implantation devices, system, and methods

    Vertex Pharmaceuticals Incorporated · Expires Jul 31, 2045

    granted
  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Jul 24, 2045

    granted
  8. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 11525120?

US 11525120 (Stem cell derived islet differentiation) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11525120?

Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.

When does US 11525120 expire?

Our index shows an expiration date of Dec 8, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.